


Resolute Onyx™ DES

SHOWN TO BE SAFE AND EFFECTIVE IN HIGHLY COMPLEX HBR PATIENTS ON 1-MONTH DAPT^{†1}


NO DIFFERENCE IN SAFETY AND EFFICACY DESPITE INCREASED LESION COMPLEXITY**

Patients with increased lesion complexity are associated with higher ischemic risk. This subanalysis from the Onyx ONE Clear analysis assessed outcomes in complex versus non-complex PCI patients.



OPTIMISED FOR COMPLEX PCI

- Truly rounded struts for easier side branch access²
- Platinum-iridium core for enhanced visibility²
- 4.5 and 5.0 mm diameters designed specifically for extra-large vessels like left main bifurcations²



Resolute Onyx is the first DES
CE indicated for 1-month DAPT
in high bleeding risk (HBR) patients

Medtronic

COMPLEX PCI PATIENTS IN THE ONYX ONE CLEAR SUB-ANALYSIS MET AT LEAST ONE CHARACTERISTIC³:

- 3 vessels treated
- ≥ 3 lesions treated
- Total stent length > 60 mm
- Bifurcation with ≥ 2 stents implanted
- Use of any atherectomy device
- Left main
- Surgical bypass graft^{††}
- Chronic total occlusion

DESIGNED DIFFERENTLY TO PROMOTE FAST HEALING⁴


Single-wire design

Increases conformability and apposition⁵




BioLinx™ polymer

Offers superior thromboresistance⁶



Less fluorescence (red) is better

Combined, these elements promote fast healing evidenced by nearly 90% strut coverage at 30 days.⁷



CE MARK INDICATIONS

1-month DAPT in HBR patients

Diabetes mellitus

In-stent restenosis (ISR)

Multivessel disease

Chronic total occlusions (CTO)

Acute coronary syndrome (ACS)

Total occlusions (TO)

Acute myocardial infarction (AMI)

Left main (LM)

Unstable angina (UA)

Small vessel (SV)

Bifurcation lesions

CE
2797

^{*}Third-party brands are trademarks of their respective owners.

[†]Based on Post-hoc analysis. Results not adjusted for multiple comparisons.

^{††}Propensity score adjusted P-values for differences in baseline characteristics.

[‡]Resolute Onyx DES is not indicated for use in surgical bypass graft.

¹Kandzari D, et al. Complex PCI with 1-month DAPT in High Bleeding Risk Patients: Analysis from the Onyx ONE Clear Study. Presented at TCT 2020.

²Medtronic data on file.

³Based on TWILIGHT Study definition: Dangas G, Baber U, Sharma S, et al. Ticagrelor With or Without Aspirin After Complex PCI. *J Am Coll Cardiol*. May 19, 2020;75(19):2414-2424.

⁴Rolerder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. *Postepy Kardiologii Interwencyjnej*. 2019;15(2):143-150.

⁵Shown in independent assessment. Data on file at Medtronic.

⁶Finn, et al. Assessment of acute thrombogenicity and albumin bindings in the Resolute Onyx Zotarolimus-eluting Coronary Stent System. Data presented at PCR 2019.

⁷Kirtane A, et al. One Month Dual Antiplatelet Therapy in High Bleeding Risk Patients: Primary Results of Onyx ONE Clear Study. Presented online at ACC 2020.

Medtronic

Europe
Medtronic Intl. Trading SARL
Tel: 41.21.802.7000

Asia Pacific
Medtronic Intl. Ltd.
Tel: 65.6436.5000

Latin America
Medtronic
Tel: 786.709.4200

[medtronic.com/OnyxONE](https://www.medtronic.com/OnyxONE)

UC202109063 ML ©2020 Medtronic. All rights reserved. Medtronic and the Medtronic logo are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. For distribution only in markets where the Resolute Onyx coronary stent has been approved. Not for distribution in Japan, France, Canada, or Australia. 10/2020

